Drug Patents Expiring in 2026

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders Jul, 2026

(3 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
15MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

2. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders Jul, 2026

(3 years from now)

US7978064 OTSUKA Communication system with partial power source Sep, 2026

(3 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

3. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758891 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US8268348 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US9101543 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2026

(3 years from now)

US8034375 ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US8268348

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US7758891

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

US9101543

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Aug, 2026

(3 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of pancreatic cancer; Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

4. Drug name - ACETADOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor May, 2026

(3 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6GM/30ML (200MG/ML) INJECTABLE;INTRAVENOUS Prescription

5. Drug name - ACTOPLUS MET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Jul, 2026

(3 years from now)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Jul, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 15MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
1GM;EQ 30MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

6. Drug name - ADASUVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8387612 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same Oct, 2026

(4 years from now)

Drugs and Companies using LOXAPINE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
10MG POWDER;INHALATION Prescription

7. Drug name - ADEMPAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(4 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
1.5MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
2.5MG TABLET;ORAL Prescription

8. Drug name - ADVAIR HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device Feb, 2026

(3 years from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
0.045MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription
0.115MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription
0.23MG/INH;EQ 0.021MG BASE/INH AEROSOL, METERED;INHALATION Prescription

9. Drug name - ADZENYS XR-ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840924 NEOS THERAPS Compositions and methods of making rapidly dissolving ionically masked formulations Apr, 2026

(3 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 3.1MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 6.3MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 9.4MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 12.5MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 15.7MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
EQ 18.8MG BASE TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription

10. Drug name - AFINITOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131

(Pediatric)

NOVARTIS Cancer treatment May, 2026

(3 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

11. Drug name - AKLIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Oct, 2026

(4 years from now)

Drugs and Companies using TRIFAROTENE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% CREAM;TOPICAL Prescription

12. Drug name - AKTEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759401 AKORN Aqueous gel formulation and method for inducing topical anesthesia Jul, 2026

(3 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Treatment: Method of inducing topical anesthesia in the eye

Dosage: GEL;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
3.5% GEL;OPHTHALMIC Prescription

13. Drug name - AMONDYS 45

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524880 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Apr, 2026

(3 years from now)

Drugs and Companies using CASIMERSEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

14. Drug name - ANDROGEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8466137 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8486925 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8759329 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8466136 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8754070 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8729057 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8741881 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8466138 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1.62% (20.25MG/1.25GM ACTUATION) GEL, METERED;TRANSDERMAL Prescription
1.62% (20.25MG/1.25GM PACKET) GEL;TRANSDERMAL Discontinued
1.62% (40.5MG/2.5GM PACKET) GEL;TRANSDERMAL Discontinued

15. Drug name - APLENZIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7569610 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt Jun, 2026

(3 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications Jun, 2026

(3 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
174MG TABLET, EXTENDED RELEASE;ORAL Prescription
348MG TABLET, EXTENDED RELEASE;ORAL Prescription
522MG TABLET, EXTENDED RELEASE;ORAL Prescription

16. Drug name - APRETUDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

Drugs and Companies using CABOTEGRAVIR ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
600MG/3ML (200MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

17. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9206135 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937B SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

CN101277937A SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN200801071P1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

IN263294B SUNOVION PHARMS INC A Process For Preparing (S) Or (R) -10,11-Dihydro-10-Hydroxy-5H-Dibenz[B,F] Azepine-5-Carboxamide
Apr, 2026

(3 years from now)

EP2319836A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP1915346A1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

EP2319836B1 SUNOVION PHARMS INC Asymmetric Catalytic Reduction Of Oxcarbazepine
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9643929 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine Apr, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

18. Drug name - ARICEPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481565 EISAI INC Method for stabilizing anti-dementia drug Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
23MG TABLET;ORAL Prescription

19. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8632804 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Dec, 2026

(4 years from now)

US8642075 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Dec, 2026

(4 years from now)

US8679532 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof Dec, 2026

(4 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults with cystic fibrosis as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

20. Drug name - ATELVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989 APIL Dosage forms of bisphosphonates Jan, 2026

(3 years from now)

Drugs and Companies using RISEDRONATE SODIUM ingredient

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
35MG TABLET, DELAYED RELEASE;ORAL Prescription

21. Drug name - ATRIPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form Jun, 2026

(3 years from now)

US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form Jun, 2026

(3 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: Treatment of hiv-1 infection in adults; treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
600MG;200MG;300MG TABLET;ORAL Prescription

22. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis Sep, 2026

(3 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: Treatment of patients with relapsing forms of multiple sclerosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

23. Drug name - AURYXIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8093423 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same Apr, 2026

(3 years from now)

Drugs and Companies using FERRIC CITRATE ingredient

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 210MG IRON TABLET;ORAL Prescription

24. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259539 KALEO INC Devices, systems and methods for medicament delivery Feb, 2026

(3 years from now)

US9278182 KALEO INC Devices, systems and methods for medicament delivery Feb, 2026

(3 years from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery Mar, 2026

(3 years from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

25. Drug name - AVYCAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5GM BASE;2GM/VIAL POWDER;INTRAVENOUS Prescription

26. Drug name - AXIRON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery Jun, 2026

(3 years from now)

US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery Jun, 2026

(3 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof

Dosage: SOLUTION, METERED;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
30MG/1.5ML ACTUATION SOLUTION, METERED;TRANSDERMAL Discontinued

27. Drug name - AXUMIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387266 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

US10010632 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

US10953112 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound Nov, 2026

(4 years from now)

Drugs and Companies using FLUCICLOVINE F-18 ingredient

Treatment: Method of diagnosing tumors using positron emission tomography

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
9-221mCi/ML SOLUTION;INTRAVENOUS Prescription

28. Drug name - AZILECT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 TEVA Rasagiline formulations and processes for their preparation Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

29. Drug name - BAXDELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252813 MELINTA Salt and crystalline forms thereof of a drug Oct, 2026

(4 years from now)

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

30. Drug name - BELEODAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6888027 ACROTECH Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(3 years from now)

Drugs and Companies using BELINOSTAT ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/VIAL POWDER;INTRAVENOUS Prescription

31. Drug name - BELRAPZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

32. Drug name - BENDEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

33. Drug name - BEVYXXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598276 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(4 years from now)

CN102336702B PORTOLA PHARMS INC Xa Factor Inhibitor N - (5-Dichloro - -2 - Pyridyl)--2-[[4 - [(Dimethylamino) Iminomethyl] Benzoyl] Amino] -5 - Benzamide Of Pharmaceutical Salts And Polymorphs
Nov, 2026

(4 years from now)

CN102336702A PORTOLA PHARMS INC Xa Factor Inhibitor N-(5-Chloro--2-Pyridyl)--2-[[4-[(Dimethylamino) Methyl] Benzoyl] Amino]--5-Methoxy-Benzamide Of Pharmaceutical Salt And Polymorph
Nov, 2026

(4 years from now)

CN101304971A PORTOLA PHARMS INC Pharmaceutical Salts And Polymorphs Of A Factor Xa Inhibitor N-(5-Chloro-2- Pyridyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide
Nov, 2026

(4 years from now)

CN101304971B PORTOLA PHARMS INC Xa Factor Inhibitor N-(5-Chloro--2-Pyridyl)--2-[[4-[(Dimethylamino) Methyl] Benzoyl] Amino]--5-Methoxy-Benzamide Of Pharmaceutical Salt And Polymorph
Nov, 2026

(4 years from now)

IN319923B PORTOLA PHARMS INC Method Of Making A Factor Xa Inhibitor
Nov, 2026

(4 years from now)

IN201400546P2 PORTOLA PHARMS INC Method Of Making A Factor Xa Inhibitor
Nov, 2026

(4 years from now)

EP1948608B1 PORTOLA PHARMS INC Pharmaceutical Salts And Polymorphs Of N-(5-Chloro-2-Pyridinyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide , A Factor Xa Inhibitor
Nov, 2026

(4 years from now)

EP1948608A2 PORTOLA PHARMS INC Pharmaceutical Salts And Polymorphs Of N-(5-Chloro-2-Pyridinyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide , A Factor Xa Inhibitor
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor Nov, 2026

(4 years from now)

Drugs and Companies using BETRIXABAN ingredient

Treatment: Prophylaxis of pulmonary embolism

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Discontinued
80MG CAPSULE;ORAL Discontinued

34. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(4 years from now)

EP1902029B1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029B2 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029A1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

35. Drug name - BRIDION

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44733 ORGANON SUB MERCK 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Jan, 2026

(3 years from now)

Drugs and Companies using SUGAMMADEX SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE/2ML (EQ 100MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 500MG BASE/5ML (EQ 100MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

36. Drug name - BRISDELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946251 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine Aug, 2026

(3 years from now)

Drugs and Companies using PAROXETINE MESYLATE ingredient

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 7.5MG BASE CAPSULE;ORAL Prescription

37. Drug name - BRIVIACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

38. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method Apr, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

39. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method Apr, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

40. Drug name - BYVALSON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ALLERGAN Compositions comprising nebivolol Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE;80MG TABLET;ORAL Discontinued

41. Drug name - CABENUVA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(3 years from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(3 years from now)

CN101212903A VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

CN101212903B VIIV HLTHCARE Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1852434B1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A1 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP1852434A4 VIIV HLTHCARE Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity
Feb, 2026

(3 years from now)

EP3045206A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2527007B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3284520A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3372281B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3045206B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP3187225B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B8 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1874117A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP2465580B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity
Apr, 2026

(3 years from now)

EP1950212A4 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212A1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

EP1950212B1 VIIV HLTHCARE Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase
Oct, 2026

(4 years from now)

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

42. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

43. Drug name - CALQUENCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

44. Drug name - CAMBIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8097651 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(3 years from now)

US7759394 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(3 years from now)

EP1890680B1 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP1890680A2 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP2402003B1 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP2705837A1 ASSERTIO Diclofenac Formulation
Jun, 2026

(3 years from now)

EP2402003A2 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP3103441B1 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP3103441A1 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

EP2705837B1 ASSERTIO Diclofenac Formulation
Jun, 2026

(3 years from now)

EP2402003A3 ASSERTIO Diclofenac Formulations And Methods Of Use
Jun, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927604 ASSERTIO Diclofenac formulations and methods of use Jun, 2026

(3 years from now)

US9827197 ASSERTIO Diclofenac formulations and methods of use Jun, 2026

(3 years from now)

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
50MG FOR SOLUTION;ORAL Prescription

45. Drug name - CERDELGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

46. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7427574 SAGE PRODS Non-woven wash cloth Apr, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
2% CLOTH;TOPICAL Over the counter

47. Drug name - CLINDESSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789057 PADAGIS US Pharmaceutical delivery system Dec, 2026

(4 years from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Treatment: Method of treating bacterial vaginosis

Dosage: CREAM;VAGINAL

More Information on Dosage
Strength Dosage Availability
EQ 2% BASE CREAM;VAGINAL Prescription

48. Drug name - CLOROTEKAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969412 B BRAUN MEDICAL INC Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture Sep, 2026

(3 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing 9-11 mg/ml chloroprocaine hcl

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
50MG/5ML (10MG/ML) SOLUTION;INTRATHECAL Prescription

49. Drug name - COLAZAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Aug, 2026

(3 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Aug, 2026

(3 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Treatment: Treatment of ulcerative colitis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
750MG CAPSULE;ORAL Prescription

50. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

51. Drug name - COMETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS c-Met modulators and methods of use
Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

52. Drug name - COREG CR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209

(Pediatric)

WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles Mar, 2026

(3 years from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

53. Drug name - CORLANOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 7.5MG BASE TABLET;ORAL Prescription

54. Drug name - CORLANOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(3 years from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(4 years from now)

CN100402502C AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600B AMGEN INC Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827600A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

CN1827602A AMGEN INC Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600485I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN200600486I1 AMGEN INC Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It
Feb, 2026

(3 years from now)

IN269993B AMGEN INC Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride
Feb, 2026

(3 years from now)

IN237447B AMGEN INC A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition
Feb, 2026

(3 years from now)

EP1695965B1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562B1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965B9 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1707562A1 AMGEN INC Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

EP1695965A1 AMGEN INC Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It
Feb, 2026

(3 years from now)

Drugs and Companies using IVABRADINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/5ML (1MG/ML) SOLUTION;ORAL Prescription

55. Drug name - COTELLIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases Oct, 2026

(4 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

56. Drug name - COTEMPLA XR-ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840924 NEOS THERAPS INC Compositions and methods of making rapidly dissolving ionically masked formulations Jun, 2026

(3 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8.6MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
17.3MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription
25.9MG TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL Prescription

57. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Sep, 2026

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

58. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

59. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435502 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers Sep, 2026

(3 years from now)

US8709392 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers Sep, 2026

(3 years from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: Treatment of acne

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1% LOTION;TOPICAL Prescription

60. Drug name - DUEXIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318202 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8449910 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8501228 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8067451 HORIZON Methods and medicaments for administration of ibuprofen Jul, 2026

(3 years from now)

US8309127 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient

Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
26.6MG;800MG TABLET;ORAL Prescription

61. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use Dec, 2026

(4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

62. Drug name - DYMISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2026

(3 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY;0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

63. Drug name - ELEPSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8535717 TRIPOINT Pharmaceutical composition Feb, 2026

(3 years from now)

US8425938 TRIPOINT Pharmaceutical composition Feb, 2026

(3 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET, EXTENDED RELEASE;ORAL Prescription
1.5GM TABLET, EXTENDED RELEASE;ORAL Prescription

64. Drug name - ELIQUIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(4 years from now)

EP1427415A1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

EP1427415A4 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

EP1427415B1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

Drugs and Companies using APIXABAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

65. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations Nov, 2026

(4 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: Treatment of heart failure

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

66. Drug name - EPANOVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS CAPSULE;ORAL Discontinued

67. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients Sep, 2026

(3 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
267MG CAPSULE;ORAL Prescription

68. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182 KALEO INC Devices, systems and methods for medicament delivery Feb, 2026

(3 years from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery Mar, 2026

(3 years from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

69. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182 KALEO INC Devices, systems and methods for medicament delivery Feb, 2026

(3 years from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery Mar, 2026

(3 years from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery Jun, 2026

(3 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

70. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

71. Drug name - FETZIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ALLERGAN Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug Jan, 2026

(3 years from now)

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 40MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 80MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 120MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

72. Drug name - FLONASE SENSIMIST ALLERGY RELIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062264 GLAXOSMITHKLINE CONS Fluid dispensing device Apr, 2026

(3 years from now)

US8752543 GLAXOSMITHKLINE CONS Fluid dispensing device Apr, 2026

(3 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.0275MG/SPRAY SPRAY, METERED;NASAL Over the counter

73. Drug name - FLOVENT HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device Feb, 2026

(3 years from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device Aug, 2026

(3 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.044MG/INH AEROSOL, METERED;INHALATION Prescription
0.11MG/INH AEROSOL, METERED;INHALATION Prescription
0.22MG/INH AEROSOL, METERED;INHALATION Prescription

74. Drug name - FYCOMPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8772497 EISAI INC Method for producing 1, 2-dihydropyridine-2-one compound
Jul, 2026

(3 years from now)

Drugs and Companies using PERAMPANEL ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG/ML SUSPENSION;ORAL Prescription

75. Drug name - GATTEX KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539310

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US7847061

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9555079

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9545434

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9545435

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9981014

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9987334

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968655

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968656

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9974837

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9974835

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9968658

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9981016

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9993528

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9987335

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9572867

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9592273

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9592274

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

US9060992

(Pediatric)

NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity May, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
5MG/VIAL POWDER;SUBCUTANEOUS Prescription

76. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8057742 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Jan, 2026

(3 years from now)

US7618594 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Oct, 2026

(4 years from now)

US7947227 VERO BIOTECH Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Oct, 2026

(4 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

77. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7176220 GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent
Aug, 2026

(3 years from now)

US7635704 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(4 years from now)

US8981103 GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound
Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

78. Drug name - GIAZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192616 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Aug, 2026

(3 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Aug, 2026

(3 years from now)

US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Aug, 2026

(3 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1.1GM TABLET;ORAL Discontinued

79. Drug name - GILENYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324283 NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Mar, 2026

(3 years from now)

US8324283

(Pediatric)

NOVARTIS Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol Sep, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription

80. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(3 years from now)

EP1345910B1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910B9 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910A1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them Jul, 2026

(3 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases Nov, 2026

(4 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

81. Drug name - HORIZANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8026279 ARBOR PHARMS LLC Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114909 ARBOR PHARMS LLC Treating or preventing restless legs syndrome using prodrugs of GABA analogs Apr, 2026

(3 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

82. Drug name - ICLUSIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors Dec, 2026

(4 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: A method of treating chronic myelogenous leukemia; a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for the treatment of leukemias; a method for treating acute lymphoblastic leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

83. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8957079 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US8735403 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US7514444 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US9181257 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase
Dec, 2026

(4 years from now)

US8697711 PHARMACYCLICS INC Inhibitors of bruton'S tyrosine kinase
Dec, 2026

(4 years from now)

CN101610676B PHARMACYCLICS INC Inhibitor Of Bruton Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101805341A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102887900B PHARMACYCLICS INC Inhibitor Of Bruton ' S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101610676A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN101805341B PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102746305A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102746305B PHARMACYCLICS INC Inhibitor Of Bruton ' S Tyrosine Kinase
Dec, 2026

(4 years from now)

CN102887900A PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

IN201205631P1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

IN362133B PHARMACYCLICS INC Inhibitors Of Bruton&Amp;Apos;S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526933A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526933B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526771A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526933A3 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526771B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2081435A4 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2530083A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2530083B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2529621A1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934A2 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2526934A3 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

EP2529621B1 PHARMACYCLICS INC Inhibitors Of Bruton'S Tyrosine Kinase
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497277 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8476284 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8754091 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8952015 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

US8703780 PHARMACYCLICS INC Inhibitors of Bruton's tyrosine kinase Dec, 2026

(4 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of chronic lymphocytic leukemia with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; Treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma; Treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; Treatment of chronic lymphocytic leukemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
70MG CAPSULE;ORAL Prescription
140MG CAPSULE;ORAL Prescription

84. Drug name - IMPLANON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant Aug, 2026

(3 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
68MG/IMPLANT IMPLANT;IMPLANTATION Prescription

85. Drug name - INREBIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7825246 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(4 years from now)

US7528143 IMPACT Bi-aryl meta-pyrimidine inhibitors of kinases
Dec, 2026

(4 years from now)

CN101370792A IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

CN101370792B IMPACT -Aryl Pyrimidine-Inhibitor-Linked Kinase
Oct, 2026

(4 years from now)

CN103626742B IMPACT Connection-Aryl-Pyrimidine Inhibitor Of Kinase
Oct, 2026

(4 years from now)

CN103626742A IMPACT -Aryl Pyrimidine-Inhibitor-Linked Kinase
Oct, 2026

(4 years from now)

IN288239B IMPACT Bi-Aryl Metapyramidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

IN200802704P4 IMPACT Bi-Aryl Meta-Pyramidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684A4 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684A1 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

EP1951684B1 IMPACT Bi-Aryl Meta-Pyrimidine Inhibitors Of Kinases
Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription

86. Drug name - ISTURISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

CN101248078B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN101248078A RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

CN102408429B RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole Derivatives Of Aromatase
Aug, 2026

(3 years from now)

CN102408429A RECORDATI RARE Inhibition Of Aldosterone Synthase And Fused Imidazole And Derivatives Of Aromatase
Aug, 2026

(3 years from now)

EP1919916A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP1919916B8 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

EP2256118B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP2256118A1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aromatase And The Treatment Of Aldosterone Related Diseases
Aug, 2026

(3 years from now)

EP1919916B1 RECORDATI RARE Condensed Imidazolo Derivatives For The Inhibition Of Aldosterone Synthase And Aromatase
Aug, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription

87. Drug name - JAKAFI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814722 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec, 2026

(4 years from now)

US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; for treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea; for treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; for treatment of steroid-refractory acute graft-versus-host disease (agvhd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

88. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

89. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

90. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

91. Drug name - JATENZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11179402 CLARUS Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Apr, 2026

(3 years from now)

IN266487B CLARUS A Pharmaceutical Composition Of Testosterone
Apr, 2026

(3 years from now)

IN200704053P2 CLARUS Oral Testosterone Ester Formulations And Methods Of Treating Testosterone Deficiency Comprising Same
Apr, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
158MG CAPSULE;ORAL Prescription
198MG CAPSULE;ORAL Prescription
237MG CAPSULE;ORAL Prescription

92. Drug name - JEVTANA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation Jun, 2026

(3 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

93. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506 BAUSCH Method for treating onychomycosis Feb, 2026

(3 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

94. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

95. Drug name - JYNARQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8501730 OTSUKA Process for preparing benzazepine compounds or salts thereof
Sep, 2026

(3 years from now)

CN102219741B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN102219741A OTSUKA For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN102746229A OTSUKA Method For Preparing Benzazepine Compound Or Salt Thereof
Sep, 2026

(3 years from now)

CN101967107B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN102746229B OTSUKA For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN101273017A OTSUKA Method For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN101273017B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

CN101967107A OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN257529B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN201205750P1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN201205723P1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN290221B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN293124B OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

IN200801507P1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

EP1919874B1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

EP2261215B1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

EP1919874A2 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

EP2251319A3 OTSUKA Process For Preparing Derivatives Of Benzoic Acid
Sep, 2026

(3 years from now)

EP2261215A1 OTSUKA Process For Preparing Benzazepine Compounds Or Salts Thereof
Sep, 2026

(3 years from now)

EP2251319B1 OTSUKA Process For Preparing Derivatives Of Benzoic Acid
Sep, 2026

(3 years from now)

EP2251319A2 OTSUKA Process For Preparing Derivatives Of Benzoic Acid
Sep, 2026

(3 years from now)

Drugs and Companies using TOLVAPTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
45MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

96. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has a r117h mutation in the cftr gene; method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has a r117h mutation in the cftr gene; Method of treating cystic fibrosis; treatment of cf in a patient age 6 months to < 6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

97. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

CN101384172B VERTEX PHARMS N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A2 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; Method of treating cystic fibrosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

98. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(3 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

99. Drug name - KOSELUGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(4 years from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(4 years from now)

CN101360718A ASTRAZENECA Novel Hydrogen Sulphate Salt
Dec, 2026

(4 years from now)

CN101360718B ASTRAZENECA Hydrosulfate
Dec, 2026

(4 years from now)

EP1968948A4 ASTRAZENECA Novel Hydrogen Sulfate Salt
Dec, 2026

(4 years from now)

EP1968948B1 ASTRAZENECA Novel Hydrogen Sulfate Salt
Dec, 2026

(4 years from now)

EP1968948A2 ASTRAZENECA Novel Hydrogen Sulfate Salt
Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 25MG BASE CAPSULE;ORAL Prescription

100. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003126

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

US7566462

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

101. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7417042 ONYX THERAP Compounds for enzyme inhibition
Jul, 2026

(3 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

102. Drug name - LATUDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555027 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8729085 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US9907794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8883794 SUNOVION PHARMS INC Pharmaceutical composition May, 2026

(3 years from now)

US8729085

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

US8883794

(Pediatric)

SUNOVION PHARMS INC Pharmaceutical composition Nov, 2026

(4 years from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

103. Drug name - LENVIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription

104. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

105. Drug name - LOCOID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7378405 BAUSCH Stabilized steroid composition and method for its preparation Dec, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
0.1% LOTION;TOPICAL Prescription

106. Drug name - LYRICA CR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144559 UPJOHN Solid pharmaceutical compositions containing pregabalin Nov, 2026

(4 years from now)

US8945620 UPJOHN Solid pharmaceutical compositions containing pregabalin Nov, 2026

(4 years from now)

US10022447 UPJOHN Solid pharmaceutical compositions containing pregabalin Nov, 2026

(4 years from now)

Drugs and Companies using PREGABALIN ingredient

Treatment: Treatment of neuropathic pain associated with diabetic peripheral neuropathy; treatment of postherpetic neuralgia; Treatment of postherpetic neuralgia; treatment of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
82.5MG TABLET, EXTENDED RELEASE;ORAL Prescription
165MG TABLET, EXTENDED RELEASE;ORAL Prescription
330MG TABLET, EXTENDED RELEASE;ORAL Prescription

107. Drug name - MAKENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180259 COVIS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US9629959 COVIS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8562564 COVIS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US9533102 COVIS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8021335 COVIS Prefilled syringe jet injector Oct, 2026

(4 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1250MG/5ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
250MG/ML (250MG/ML) SOLUTION;INTRAMUSCULAR Prescription
275MG/1.1ML (250MG/ML) SOLUTION;SUBCUTANEOUS Prescription

108. Drug name - MAVENCLAD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis May, 2026

(3 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis Oct, 2026

(4 years from now)

Drugs and Companies using CLADRIBINE ingredient

Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1.7 mg/kg cladribine; (iv) cladribine-free period; Treating ms with oral cladribine acc. to the steps (i) induction period with about 1.7 mg/kg-3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) maintenance period with about 1.7 mg/kg cladribine; (iv) cladribine-free period

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

109. Drug name - MITOSOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205075 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application Jul, 2026

(3 years from now)

US8186511 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application Jul, 2026

(3 years from now)

Drugs and Companies using MITOMYCIN ingredient

Treatment: NA

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.2MG/VIAL FOR SOLUTION;TOPICAL Prescription

110. Drug name - MOXATAG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8778924 PRAGMA Modified release amoxicillin products
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357394 PRAGMA Compositions and methods for improved efficacy of penicillin-type antibiotics Dec, 2026

(4 years from now)

Drugs and Companies using AMOXICILLIN ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
775MG TABLET, EXTENDED RELEASE;ORAL Discontinued

111. Drug name - MYDAYIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system May, 2026

(3 years from now)

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

112. Drug name - NAMZARIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions May, 2026

(3 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
10MG;7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

113. Drug name - NAPROXEN SODIUM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693979 BIONPHARMA INC Liquid dosage forms of sodium naproxen Mar, 2026

(3 years from now)

US11090280 BIONPHARMA INC Liquid dosage forms of sodium naproxen Mar, 2026

(3 years from now)

US10022344 BIONPHARMA INC Liquid dosage forms of sodium naproxen Mar, 2026

(3 years from now)

US10028925 BIONPHARMA INC Liquid dosage forms of sodium naproxen Mar, 2026

(3 years from now)

US9693978 BIONPHARMA INC Solvent system for enhancing the solubility of pharmaceutical agents Mar, 2026

(3 years from now)

Drugs and Companies using NAPROXEN SODIUM ingredient

Treatment: Temporary relief of minor aches and pains; temporary reduction of fever

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Over the counter

114. Drug name - NAROPIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7857802 FRESENIUS KABI USA Connector for medical liquid-containing packages and medical liquid-containing packages Nov, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM/200ML (5MG/ML) SOLUTION;INJECTION Prescription
50MG/10ML (5MG/ML) SOLUTION;INJECTION Discontinued
20MG/10ML (2MG/ML) SOLUTION;INJECTION Prescription
40MG/20ML (2MG/ML) SOLUTION;INJECTION Prescription
75MG/10ML (7.5MG/ML) SOLUTION;INJECTION Discontinued
100MG/20ML (5MG/ML) SOLUTION;INJECTION Prescription
100MG/10ML (10MG/ML) SOLUTION;INJECTION Prescription
150MG/20ML (7.5MG/ML) SOLUTION;INJECTION Prescription
150MG/30ML (5MG/ML) SOLUTION;INJECTION Prescription
200MG/100ML (2MG/ML) SOLUTION;INJECTION Prescription
200MG/20ML (10MG/ML) SOLUTION;INJECTION Prescription
400MG/200ML (2MG/ML) SOLUTION;INJECTION Prescription
500MG/100ML (5MG/ML) SOLUTION;INJECTION Prescription

115. Drug name - NATAZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071577 BAYER HLTHCARE Multi-phase contraceptive preparation based on a natural estrogen May, 2026

(3 years from now)

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A TABLET;ORAL Prescription

116. Drug name - NUEDEXTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659282 AVANIR PHARMS Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders Aug, 2026

(3 years from now)

Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient

Treatment: Treatment of pseudobulbar affect

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;10MG CAPSULE;ORAL Prescription

117. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659285 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Aug, 2026

(3 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of parkinson's disease psychosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 17MG BASE TABLET;ORAL Discontinued

118. Drug name - OLYSIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9856265 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8754106 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8349869 JANSSEN PRODS Macrocylic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US9040562 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

US8741926 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus
Jul, 2026

(3 years from now)

IN294307B JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

IN200710158P1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP2322516A1 JANSSEN PRODS Intermediates For The Preparation Of Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP2322516B1 JANSSEN PRODS Intermediates For The Preparation Of Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1912999A1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1912999B1 JANSSEN PRODS Macrocyclic Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9353103 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus Jul, 2026

(3 years from now)

US9623022 JANSSEN PRODS Macrocyclic inhibitors of hepatitis C virus Jul, 2026

(3 years from now)

Drugs and Companies using SIMEPREVIR SODIUM ingredient

Treatment: Method of treating hepatitis c

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Discontinued

119. Drug name - OMONTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued

120. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors Jul, 2026

(3 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

121. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide Sep, 2026

(3 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

122. Drug name - OPZELURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974790 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec, 2026

(4 years from now)

US10639310 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

US9079912 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec, 2026

(4 years from now)

Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient

Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 1.5% BASE CREAM;TOPICAL Prescription

123. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7417070 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393203 UNITED THERAP Osmotic drug delivery system Apr, 2026

(3 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

124. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7973038 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US9216969 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US8741933 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor; Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor; method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; Method of treating cystic fibrosis in a patient age 6 or older homozygous for the f508del mutation in the cftr gene using lumacaftor and a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
125MG;100MG TABLET;ORAL Prescription
125MG;200MG TABLET;ORAL Prescription

125. Drug name - OSPHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236861 DUCHESNAY Method for enhancing the bioavailablity of ospemifene Aug, 2026

(3 years from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

126. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9533102 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8562564 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US9629959 OTTER PHARMS Prefilled syringe jet injector Jan, 2026

(3 years from now)

US8021335 OTTER PHARMS Prefilled syringe jet injector Oct, 2026

(4 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

127. Drug name - OVIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977324 TARO PHARM INDS LTD Process for preparing malathion for pharmaceutical use Aug, 2026

(3 years from now)

Drugs and Companies using MALATHION ingredient

Treatment: NA

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.5% LOTION;TOPICAL Discontinued

128. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

CN101133082A NOVO Acylated Glp-1 Compound
Mar, 2026

(3 years from now)

CN101133082B NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

IN262697B NOVO Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue
Mar, 2026

(3 years from now)

IN200705107P1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP2322546A1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839B1 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

EP1863839A2 NOVO Acylated Glp-1 Compounds
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376652 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism Jan, 2026

(3 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism Jan, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul, 2026

(3 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechani